Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$5.08M-$5.08MderivedN/M vs Q4 2021 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$5,119,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,599,000N/M Free Cash Flowderived-$4,597,000N/M ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end